CDK4 and CDK6 drugs for HR+/HER2- Metastatic Breast Cancer

6 tracked CDK4 and CDK6 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the CDK4 and CDK6 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.

3 approved / phase 42 Phase 31 Phase 2/3

Head-to-head evidence: Abemaciclib vs Dalpiciclib · Abemaciclib vs Palbociclib · Abemaciclib vs Ribociclib · Abemaciclib vs SPH4336 · Abemaciclib vs Tibremciclib · Dalpiciclib vs Palbociclib

The roster

← all CDK4 and CDK6 drugs